Ankylosing Spondylitis News and Research

RSS
Ankylosing Spondylitis (AS) is a painful and progressive form of spinal arthritis and symptoms of inflammatory back pain often first present in people before age 35. It typically begins in the late teens and early twenties and in severe cases may result in fusing spinal vertebrae and may cause structural damage to hips and other joints. Often misdiagnosed as "just back pain" or undifferentiated arthritis, AS is a systemic inflammatory disease that, in addition to its effect on the spine, can affect internal organs, peripheral joints and vision. The Arthritis Research Campaign, estimates that on the European continent, AS prevalence ranges from 0.2 to 1 percent of the entire population. The Spondylitis Association of America estimates that between 350,000 and one million people in the U.S. suffer from Ankylosing Spondylitis.
Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

Cervical spine CT exams unnecessary for simple assault and ground-level fall victims

Cervical spine CT exams unnecessary for simple assault and ground-level fall victims

Lilly's ixekizumab Phase II trial on plaque psoriasis meets primary endpoint

Lilly's ixekizumab Phase II trial on plaque psoriasis meets primary endpoint

Abbott initiates enrollment in two HUMIRA Phase 3 trials for moderate to severe HS

Abbott initiates enrollment in two HUMIRA Phase 3 trials for moderate to severe HS

Questcor fourth quarter net sales increase to $75.5 million

Questcor fourth quarter net sales increase to $75.5 million

Study implicates 'arms race' between genes and germs

Study implicates 'arms race' between genes and germs

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

PDUFA goal date of NDA for Protalix's taliglucerase alfa extended

PDUFA goal date of NDA for Protalix's taliglucerase alfa extended

TNF inhibitors may minimally increase risk of serious infections

TNF inhibitors may minimally increase risk of serious infections

Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis

Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott announces results from HUMIRA Phase 3 study on axSpA

Potential predictors of spinal damage progression in people with spondyloarthritis

Potential predictors of spinal damage progression in people with spondyloarthritis

POZEN third quarter revenue increases to $4.9 million

POZEN third quarter revenue increases to $4.9 million

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Janssen Biotech receives FDA approval for Remicade to treat UC in children

Janssen Biotech receives FDA approval for Remicade to treat UC in children

HealthWell Foundation introduces new lupus fund

HealthWell Foundation introduces new lupus fund